ISSN 2590-0048
Vol. 4, Issue 4, 2022August 23, 2022 CDT
Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
Shamis Khan, Sara Taveras Alam, Rosa Torres Ramos, John Etumbani Mbue, Effrosyni Apostolidou, Gustavo A. Rivero, Sarvari Venkata Yellapragada,
Articles in Vol. 4, Issue 4, 2022
Vol. 4, Issue 4, 2022
- ‘Standing on the Shoulders of the Giants’: Dr Rainer StorbMohamad MohtyRainer Storb
- Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and PerspectiveAhmad IbrahimNabil ChamseddineJean El-cheikhColette HannaWalid MoukademFady NasrAhmad YounisAli Bazarbachi
- Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) StudyAnn JanssensZwi N. BernemanFritz OffnerSylvia SnauwaertPhilippe MineurGaetan VanstraelenStef MeersIsabelle SpoormansDominique BronIsabelle Vande BroekCharlotte Van BogaertBirgit De BeleyrAnn SmetLasse NielsenRobert WapenaarMarc André
- Effects of Erythrocytapheresis Procedures on Delayed Bone Marrow Conversion in Sickle Cell DiseaseEmily PophamKaren MoellerAshok Raj
- Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case SeriesShamis KhanSara Taveras AlamRosa Torres RamosJohn Etumbani MbueEffrosyni ApostolidouGustavo A. RiveroSarvari Venkata Yellapragada
Khan, Shamis, Sara Taveras Alam, Rosa Torres Ramos, John Etumbani Mbue, Effrosyni Apostolidou, Gustavo A. Rivero, and Sarvari Venkata Yellapragada. 2022. “Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series.” Clinical Hematology International 4 (4): 148–51. https://doi.org/10.1007/s44228-022-00016-4.